Loading clinical trials...
Loading clinical trials...
A Phase Ib/II, Multi-center, Open-label Study to Evaluate the Efficacy of AUY922 in Combination With Trastuzumab in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer, That Has Progressed After or During at Least One Trastuzumab-containing Regimen
Conditions
Interventions
AUY922
Trastuzumab
Locations
16
United States
Highlands Oncology Group Dept of Highlands Oncology Grp
Fayetteville, Arkansas, United States
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Saint-Herblain Cédex, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Tübingen, Germany
Novartis Investigative Site
Prato, PO, Italy
Start Date
September 1, 2010
Primary Completion Date
October 1, 2013
Completion Date
October 1, 2013
Last Updated
December 8, 2020
NCT01921335
NCT01602406
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions